Pemetrexed is a multitarget anticancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.
Pemetrexed is for Intravenous Infusion only
Combination Use With Cisplatin:
Malignant Pleural Mesothelioma:
The recommended dose of pemetrexed is 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 infused over 2 hours beginning approximately 30 minutes after the end of pemetrexed administration. Patients should receive hydration consistent with local practice prior to and / or after receiving cisplatin. (for details see cisplatin pack insert)
Non-Small Cell Lung Cancer:
The recommended dose of Pemetrexed is 500 mg/m2 administered as an intravenous infusion over 10minutes on Day 1 of each 21-day cycle.
Kabipem (Pemetrexed) used in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or in subjects where curative surgery can’t be performed.
Kabipem (pemetrexed) as a single-agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy.
Kabipem Injection 500 mg (pemetrexed) is available in sterile single-use vials containing 500 mg pemetrexed.
Kabipem Injection 100 mg (pemetrexed) is available in sterile single-use vials containing 100 mg pemetrexed.